ISSN: 1868-8497

Journal Home

Journal Guideline

Hormones and Cancer Q2 Unclaimed

Springer US United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Hormones and Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 40. It has a price of 2040 €. It has a best quartile of Q2.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q2) Cancer Research (Q3) Endocrine and Autonomic Systems (Q3) Endocrinology (Q3) Endocrinology, Diabetes and Metabolism (Q3) Endocrinology, Diabetes and Metabolism (Q3) Oncology (Q3)

Price

2040 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

-

SJR Impact factor

40

H Index

0

Total Docs (Last Year)

85

Total Docs (3 years)

0

Total Refs

361

Total Cites (3 years)

83

Citable Docs (3 years)

4.5

Cites/Doc (2 years)

0.0

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

International Journal of Oncology Q2
BMC Cancer Q2
Cancer Epidemiology Q2
Frontiers in Oncology Q2
Journal of Geriatric Oncology Q2

Compare this journals

Aims and Scope

Best articles by citations

16-kDa Prolactin Reduces Angiogenesis, but Not Growth of Human Breast Cancer Tumors In Vivo

Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort

Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer

A Bright Future for Hormones and Cancer: Farewell Comments of Dr. Carol A. Lange, Recent Past Editor-in-Chief

CREB-Regulated Transcription Co-Activator Family Stimulates Promoter II-Driven Aromatase Expression in Preadipocytes

Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer

Letter from the Editor

Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide

Expression and In Vitro Functions of the Ghrelin Axis in Endometrial Cancer

Downregulation of IGF1R Expression Inhibits Growth and Enhances Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cells In Vitro

Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice

SHOW MORE ARTICLES

Thyroid Hormone in the Clinic and Breast Cancer

Frequent Germ-Line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism

Gene Expression Profiling Reveals Differentially Expressed Genes in Ovarian Cancer of the Hen: Support for Oviductal Origin?

Relationship of Serum Estrogens and Metabolites with Area and Volume Mammographic Densities

Negative Regulation of the Androgen Receptor Gene Through a Primate-Specific Androgen Response Element Present in the 5' UTR

Symptomatic Control of Neuroendocrine Tumours with Everolimus

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis

Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond

Altered PTEN, ATRX, CHGA, CHGB, and TP53 Expression Are Associated with Aggressive VHL-Associated Pancreatic Neuroendocrine Tumors

Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene

Suppression of Metastatic Murine Ovarian Cancer Cells by Transduced Embryonic Progenitor Cells

Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation